The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I traded mtfb in the past and made loads but also lost loads. Most investors lost out big time for sure. 2mr gonna be a bit of fun investing in the old lady
Forgot to add this!
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.
If you think that their is something seriously wrong with your research....can’t do this for you unfortunately! Either you have it or don’t lol
https://www.youtube.com/watch?v=p3HQzzZQhpI
24th May 2019 - 1:10 This is a video of Graham Lumsden talking about Iclaprim (Motif bio) and LMS611 (Lamellasome) Working together to treat Staphylococcus Aureus pneumonia in cystic fibrosis. Iclaprim already have an 'Orphan status' in USA.
RNS Today:
Appointment of Chris Wardhaugh is appointed as a Non-Executive Director;
Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.
Yes difficult to get a quote with this stock, but if you keep trying you will get one. It’ll be very hard buying this again tomorrow morning as demand has hit the roof and their is a shortage of shares...a classic case!
Thanks eviking, it definitely looks like the way we're going. Price could go crazy from here (again) !!!
I made here in the past and then lost on the valentine massacre. Cant help feeling this is still just a binary pipe dream but if the Director changes and Lamellar link are founded on more than vague speculation this could have legs. If Trump will support swallowing disinfectant what might the FDA now so with this drug or Lamellar be able to bolt it on to . In at out today for a free ride with what I hold but good luck all LTHs who may recoup (some) losses here
Can i share my trades today, sold 396k for a 68 quid profit, as it started dropping after the initial rise, watched it go up, found it difficult to buy, then bought 94k for 1k, same as what i sold!! You have to laugh.
If you got the balls trade 2mr. But it is after all a RTO. You could be left with nothing.
The old timers Latino and Kettle never gave up and kept many of us holding in hope...
Big thank you to both ..
Possibly 3-5p..
Hi
Well done to anyone who actually bought into this today! Having recently been laid off I thought I’d give the stock market ago again after a 10 year absence. I thought I’d done well on my last trade back then getting a 3 bagger over two weeks (Dominion Oils I think) so amazing that some of you have down a 8 bagger in one day. Thankfully I did so the foolish thing and put all my savings into one basket so glad it paid off. Not a clever/recommended normal strategy....!
Rather than dive back in, I thought I’d play with a mock account and just watch. MTBF was One of my stocks (as was VAL) and I did try and buy MTBF twice when I couldn’t control my will power - first time around lunchtime then around 3pm. Both times I couldn’t buy via ii.co.uk real time, I think it said I’d have to place an order. I was just wondering how some of you were able to buy and more importantly sell! Any advice greatly received :)
On the bell....hugh squeeze and extortionate demand for these at close...gla
Thoughts for tomorrow everyone?
Cp00
Yes the connection is ace. Good post
Lol - put into context guys, this was trading 40p when FDA announced they want more data!
It’s a different ball game now as were 1.4p
I can't spell toxcinity. Sorry guy's, working from home. ****ed by 2.30 - Toxcicyty... Toxicity.
Pebsi correct
Ivyspikey was a valued poster. So was many others
FDA needed more data. mtfb were so confident they didn't budget for it. That's why it's on its knees even at 10p and GL gets a hard time. FDA needed more info on liver tovixity even though the liver returns to normal after treatment (mtfb couldn't afford to do that). Any other LTH want to pitch in? This all happened before CV19, when the biggest threat to mankind was bacteria not bothered by our FDA approved AB drugs. mtfb had a new AB that was extremely promising apart from the afore mentioned.
THis is the new appointment to the board and his experience and directorship of Lameller is the clue to an RTO.
Christopher (Chris) Wardhaugh
Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.
Chris has over 28 years’ experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.
Commenting, Bruce Williams, Chairman of Motif Bio, said: “We welcome Chris to the Board as we focus on sourcing an appropriate reverse takeover candidate for Motif Bio. We believe that the Company will benefit from Chris’s breadth of knowledge and transactional experience and we will provide shareholders with further updates in due course.”
The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication
Moneynutch I think you just did
sease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology
....................
A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-us
sease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.
8/4/20
Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology
....................
A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.
The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.
Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."
Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."
hTtps://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-us
Oldfinger thats what I will be making for my dinner....Sheeeeeeeesh Kebab to celeberate revival of Motif